Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Hadoux J, Walter T, Kanaan C, Hescot S, Hautefeuille V, Perrier M, Tauveron I, Laboureau S, Do Cao C, Petorin C, Blanchet O, Faron M, Leteurtre E, Rousselet MC, Joubert Zakeyh J, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Lombard-Bohas C, Ducreux M, Scoazec JY, Baudin E; Groupe d’Etude des Tumeurs Endocrines (GTE); ENDOCAN-RENATEN network.
Hadoux J, et al. Among authors: kanaan c.
Endocr Relat Cancer. 2022 Aug 17;29(10):569-580. doi: 10.1530/ERC-22-0102. Print 2022 Oct 1.
Endocr Relat Cancer. 2022.
PMID: 35920609